Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NNOX.
← Back to Free Index

NNOX

Analysis as of: 2026-04-21
Nano-X Imaging Ltd.
Nanox sells digital imaging systems, teleradiology services, AI imaging software, and health IT workflow tools to healthcare providers and imaging partners.
ai healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Installed Imaging Option, Not Yet a Platform
The upside is real if system activations start to pull through recurring reading and workflow revenue. The risk is that signed agreements stay ahead of operational proof, forcing more dilution before scale economics show up.

Analysis

Thesis
Nanox is a high-variance option on turning a cleared low-cost imaging device into a recurring imaging utility; if distributor volume converts into activated systems with reading, AI, and workflow attach, revenue can scale faster than the market expects even without a software-style premium.
Last Economy Alignment
Positive but not elite: AI makes reading and workflow cheaper, and each activated scanner can pull through service revenue, but the real bottleneck is regulated hardware deployment.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
5.4x (from 5 most recent analyses)
Reasoning
Revenue is the right lens because the business is too early for cash-flow valuation. If Nanox proves that installed systems activate and pull through reading, AI, and health IT revenue, the market can value it as a regulated imaging-services stack rather than a speculative device story. I still use a restrained hybrid multiple because recurring mix should improve, but not enough to deserve premium software treatment.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is sequence failure: signed demand must turn into activated, reimbursed sites before cash burn forces more dilution. If deployments stay slow, larger imaging vendors can out-bundle the workflow layer, gross margins remain weak, and Nanox stays a financing story rather than an imaging utility platform.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.31
They control a cleared imaging device plus the reading and workflow around it, so every working scanner can pull through more service revenue. But bigger incumbents still own trust and distribution, and if installations stay slow the software layer will be easy to out-bundle.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case